Henderson Merle, Blenkinsop Alexandra, Ratmann Oliver, Cheung Moira, Lyall Hermione, Fidler Sarah, Foster Caroline
Department of Infectious Diseases, Imperial College London, London, UK.
900 Clinic, Imperial College Healthcare NHS Trust, London, UK.
J Int AIDS Soc. 2025 Sep;28(9):e70029. doi: 10.1002/jia2.70029.
Low bone mineral density (BMD) has been described in children and young people with perinatally acquired HIV (PHIV), which may be related to both traditional (e.g. low body mass index and malnutrition) and HIV-related risk factors (e.g. longstanding exposure to HIV and antiretroviral therapy [ART], with immune suppression, chronic immune activation and inflammation). Here, we evaluate BMD in a U.K. cohort of young people with PHIV by age and ART.
This longitudinal, observational study was conducted at a U.K. tertiary PHIV service between November 2018 and March 2022. Bone health was assessed in 130 individuals aged 15-19 (n = 50), 20-24 (n = 50) and 25 years and older (n = 30) by dual-energy X-ray absorptiometry, bone mineralization and turnover markers. Low BMD was defined as lumbar spine (LS) and/or femur-BMD z-score below -2, relative to age, sex and ethnicity-matched U.K. population-based normative controls. Two-year follow-up evaluation was performed in those aged 15-19 (n = 42) and 20-24 years (n = 43) at enrolment, which included a group who switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) ART at baseline. Bayesian logistic regression models examined predictors of low BMD and the effect of ART-backbone on BMD accrual.
At baseline, 57% were female and 82% of black ethnicity, with 31 (24%) on TDF-ART. Sixteen (12%) had low baseline BMD. Over a median follow-up duration of 26 (interquartile range [IQR] 25-29) months, BMD accrual was lower-than-expected in those aged 15-19 years (mean change LS-BMD z-score -0.15 (standard deviation [SD] 0.44)), when compared to normative controls. No associations were seen with HIV parameters or the ART regimen. Participants who switched to TAF-ART had similar BMD accrual 26 (IQR 24-32) months post switch, when compared to those on non-TAF/TDF-ART (mean change LS-BMD z-score TAF -0.01 [SD 0.41] vs. non-TAF/TDF -0.03 [SD 0.54]).
While rates of low BMD were reassuringly low in this cohort, lower-than-expected BMD accrual was observed in younger individuals, relative to normative controls. Overall, BMD accrual on TAF-ART was non-inferior to non-TAF/TDF-ART.
围产期感染艾滋病毒(PHIV)的儿童和年轻人中存在低骨矿物质密度(BMD)的情况,这可能与传统风险因素(如低体重指数和营养不良)以及与艾滋病毒相关的风险因素(如长期接触艾滋病毒和抗逆转录病毒疗法[ART],伴有免疫抑制、慢性免疫激活和炎症)有关。在此,我们按年龄和抗逆转录病毒疗法评估了英国一组感染PHIV的年轻人的骨矿物质密度。
这项纵向观察性研究于2018年11月至2022年3月在英国一家三级PHIV服务机构进行。通过双能X线吸收法、骨矿化和骨转换标志物对130名年龄在15 - 19岁(n = 50)、20 - 24岁(n = 50)和25岁及以上(n = 30)的个体进行骨健康评估。相对于年龄、性别和种族匹配的英国人群标准对照,低骨矿物质密度定义为腰椎(LS)和/或股骨骨矿物质密度z评分低于 -2。对入组时年龄在15 - 19岁(n = 42)和20 - 24岁(n = 43)的参与者进行了为期两年的随访评估,其中包括一组在基线时从富马酸替诺福韦二吡呋酯(TDF)转换为替诺福韦艾拉酚胺(TAF)抗逆转录病毒疗法的人群。贝叶斯逻辑回归模型检查了低骨矿物质密度的预测因素以及抗逆转录病毒疗法主干对骨矿物质密度增加的影响。
基线时,57%为女性,82%为黑人种族,31人(24%)接受TDF抗逆转录病毒疗法。16人(12%)基线骨矿物质密度较低。在中位随访期为26(四分位间距[IQR] 25 - 29)个月期间,与标准对照相比,15 - 19岁人群的骨矿物质密度增加低于预期(腰椎骨矿物质密度z评分平均变化 -0.15(标准差[SD] 0.44))。未发现与艾滋病毒参数或抗逆转录病毒疗法方案有关联。与接受非TAF/TDF抗逆转录病毒疗法的参与者相比,转换为TAF抗逆转录病毒疗法的参与者在转换后26(IQR 24 - 32)个月时骨矿物质密度增加相似(腰椎骨矿物质密度z评分平均变化TAF为 -0.01 [SD 0.41],非TAF/TDF为 -0.03 [SD 0.54])。
虽然该队列中低骨矿物质密度的发生率令人放心地低,但相对于标准对照,较年轻个体的骨矿物质密度增加低于预期。总体而言,TAF抗逆转录病毒疗法的骨矿物质密度增加不劣于非TAF/TDF抗逆转录病毒疗法。